103 related articles for article (PubMed ID: 28162289)
1. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
Kashfi K
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
[TBL] [Abstract][Full Text] [Related]
2. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
3. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
[TBL] [Abstract][Full Text] [Related]
4. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
5. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
[TBL] [Abstract][Full Text] [Related]
7. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
Vannini F; Kodela R; Chattopadhyay M; Kashfi K
Redox Biol; 2015 Aug; 5():421. PubMed ID: 28162291
[TBL] [Abstract][Full Text] [Related]
8. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
Kashfi K; Chattopadhyay M; Kodela R
Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
[TBL] [Abstract][Full Text] [Related]
9. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders.
Lee M; McGeer E; Kodela R; Kashfi K; McGeer PL
Glia; 2013 Oct; 61(10):1724-34. PubMed ID: 23918470
[TBL] [Abstract][Full Text] [Related]
10. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
11. NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.
Kodela R; Chattopadhyay M; Kashfi K
ACS Med Chem Lett; 2012 Mar; 3(3):257-262. PubMed ID: 22916316
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
13. NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain.
Fonseca MD; Cunha FQ; Kashfi K; Cunha TM
Pharmacol Res Perspect; 2015 Jun; 3(3):e00133. PubMed ID: 26236481
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.
Kodela R; Chattopadhyay M; Kashfi K
Medchemcomm; 2013; 4(11):. PubMed ID: 24273639
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in
Antoniou C; Xenofontos R; Chatzimichail G; Christou A; Kashfi K; Fotopoulos V
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936819
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological Effects.
Zhou J; Zeng W; Zeng Y; Li Y; Xiao Z; Zou J; Peng L; Xia J; Zeng X
Comput Math Methods Med; 2022; 2022():4463294. PubMed ID: 36035295
[TBL] [Abstract][Full Text] [Related]
18. Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.
Mattheolabakis G; Papayannis I; Yang J; Vaeth BM; Wang R; Bandovic J; Ouyang N; Rigas B; Mackenzie GG
Cancer Prev Res (Phila); 2016 Jul; 9(7):624-34. PubMed ID: 27138793
[TBL] [Abstract][Full Text] [Related]
19. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Gao M; Kong Q; Hua H; Yin Y; Wang J; Luo T; Jiang Y
Oncotarget; 2016 Mar; 7(13):16349-61. PubMed ID: 26918349
[TBL] [Abstract][Full Text] [Related]
20. SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy.
Wong CC; Lim SH; Sagineedu SR; Lajis NH; Stanslas J
Pharmacol Res; 2016 May; 107():66-78. PubMed ID: 26940565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
